Idorsia on course to take on Eisai and Merck & Co after latest insomnia phase 3 trial winSwitzerland’s Idorsia says it is on course to file a potential next-generation insomnia drug around the end of this year after a Share XIdorsia on course to take on Eisai and Merck & Co after latest insomnia phase 3 trial winhttps://pharmaphorum.com/news/idorsia-on-course-to-take-on-eisai-and-merck-co-after-latest-insomnia-phase-3-trial-win/
Neurocrine signs $400M-plus deal with Idorsia for epilepsy drugSwiss biotech Idorsia and Neurocrine Biosciences of the US have amended a deal signed last year to develop Share XNeurocrine signs $400M-plus deal with Idorsia for epilepsy drughttps://pharmaphorum.com/news/neurocrine-signs-400m-plus-deal-with-idorsia-for-epilepsy-drug/
